Patent ID: 9671404
Date: 2017-06-06
CPC Classifications: A61P,G01N

Claim:
1. A method for treating a patient suffering from metastatic renal cell carcinoma or metastatic adenocarcinoma that has been pretreated with cyclophosphamide, comprising: a) obtaining a biological sample comprising peripheral blood mononuclear cells (PBMC) from said patient; b) contacting the biological sample with a detectably-labeled antibody specific for CD11b, a detectably-labeled antibody specific for CD14, a detectably-labeled antibody specific for CD15, a detectably-labeled antibody specific for CD80, a detectably-labeled antibody specific for CD83, a detectably-labeled antibody specific for CD86, and a detectably-labeled antibody specific for HLA-DR; c) quantitating the level of myeloid-derived suppressor cells having MDSC5 phenotype in the patient relative to the level of myeloid-derived suppressor cells having MDSC5 phenotype in a non-treated patient sample by flow cytometry, wherein said MDSC5 phenotype is based on markers CD11b+, CD14−, CD15+, FSChi, SSCim, CD80−, CD83−, CD86−, and HLA-DR-; and d) administering an anti-cancer vaccine to said patient if the level of myeloid-derived suppressor cells having MDSC5 phenotype from step (c) is decreased compared to a non-treated patient sample, wherein said anti-cancer vaccine is selected from an anti-cancer vaccine comprising a mixture of immunogenic peptides having a sequence selected from SEQ ID No. 1 to 10; SEQ ID No. 11 to 19 and 1, 5, 8, and 9; SEQ ID No. 20 to 29, and SEQ ID No. 30 to 37.